Isodiol International Inc (OTCMKTS: ISOLF) has been running up the charts in recent days on a fast acceleration of volume.The stock has a long history of big moves skyrocketing at the end of last year.
Earlier this month ISOLF announced it will hold its annual general meeting of the Company’s shareholders (the “Meeting”) at 10:00 a.m. (Central Time) on June 6, 2019, at the Westin Santa Fe Hotel (Ballroom A) in Mexico City, Mexico.
“It is a pleasure to host Isodiol and its directors and shareholders in my home city and demonstrate the Company’s commitment to Mexico and Latin America,” said Leonardo Matesanz, a Director of Isodiol. “Isodiol has been involved in various efforts in recent years to position itself as a market leader in Mexico once appropriate regulations are in place. We are now confident that the Mexican authorities are developing a path to legalization of our products and look forward to bringing them to consumers throughout the country soon.”
Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) initially published regulations for CBD products on October 30, 2018, which indicated that products made from hemp were industrial products that could be traded as cosmetics, supplement foods, and herbal products. CBD medicines also were included in the regulations, subject to clinical trials and proper protocols. However, those regulations and the licenses initially awarded by COFEPRIS were revoked on March 27, 2019, leaving the industry’s future in question. Nevertheless, the Mexican Senate stated in March 2019 that “legalization is imminent,” with medical and scientific regulations expected to be issued by October 2019.
Isodiol established operations in Mexico in 2017 with the intent to take advantage of the initial regulations that ultimately were released by COFEPRIS on October 30, 2018. However, based upon concerns about the validity of those regulations and the licenses issued to Isodiol’s competitors, Isodiol strategically safeguarded its opportunities and withheld application for licensure under the initial regulations.
Isodiol International Inc (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is a growth through acquisition story; Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its consumer products portfolio and aggressively continue international expansion into Latin America, Asia, and Europe.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodial is seeing significant growth; the Company recently reported first quarter revenue of $9.2 million, representing an approximate 240% increase over the quarter ended June 30, 2017 and an approximate 70% increase over revenues of $5.4 million in the fourth quarter of fiscal 2018.
2018 has been a big year for Isodiol; they received government Approval from United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Pure, Natural CBD as an Active Pharmaceutical Ingredient (API) They Completed the Acquisition of KURE Corp and also announced KURE expansion plans.
To Find out the inside Scoop on Isodiol Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In May they acquired a turn-key brewing system, including a 7-bbl brewhouse, four 15-bbl fermentation tanks, a 30-bbl fermentation tank, a 15-bbl brite tank, and a 30-bbl brite tank, which is expected to yield between 1,500 and 2,000 bbls of production per year. In addition, IsoBev acquired a 12-ounce bottling line and a 22-ounce bottling line, which could yield over 600,000 12-oz bottles and 25,000 12-oz bottle cases per year.
The Company also launched ISOCare in North American and Latin American markets in conjunction with Livecare. ISOCare is an innovative secure platform for the cannabis treatment industry that enables and supports physicians in the longitudinal care of their patients’ health. The Company had previously announced its licensing agreement with Livecare on January 26, 2018.
ISOCare will allow collaborative care with doctors and mentor certified cannabis practitioners to achieve health outcomes including medicinal cannabis therapies. The ISOCare platform connects patients with providers for a medical visit, through a mobile or PC device, eliminating many of the inconveniences faced today in the physician and patient relationship. To access the ISOCare platform, patients must simply complete their initiation form, which doctors then review before connecting with patients via video conference. From there, physicians may prescribe medications, or discuss any other concerns.
Last month Isodiol entered into an agreement with Powerhouse Gym, one of the largest health club licensing organization in the world, through the Company’s wholly owned subsidiary, Iso-Sport, to be the preferred vendor of CBD Performance Products offered to its over 1.2 million gym members1.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $45 million market valuation Isodiol has $11.5 million in the treasury, $32 million in current assets and significant debt with $63 million in current liabilities. Isodiol is an exciting Company that has seen explosive growth through acquisition recently reported first quarter revenue of $9.2 million, representing an approximate 240% increase over the quarter ended June 30, 2017 and an approximate 70% increase over revenues of $5.4 million in the fourth quarter of fiscal 2018. The stock has quickly attracted a loyal shareholder base who continues to bid this one higher. We will be updating on Isodiol when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Isodiol.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in Isodiol either long or short and we have not been compensated for this article.